Phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin Lymphoma

Started in November 2012, updated in June 2014, the trial is recruiting patients in Edmonton, Vancouver and Montreal:

Official Title

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Summary:

This open-label, randomized, 2-arm, multicentre, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Trial Description

Primary Outcome:

Modified progression free survival (mPFS) per independent review facility (IRF)

See more details here.